Pediatric regimens have improved outcomes in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL). However, results remain inferior to children with ALL. The ALLG ALL06 study (anzctr.org.au/ACTRN12611000814976) was designed to assess whether a pediatric ALL regimen (ANZCHOG Study 8) could be administered to patients aged 15-39 years in a comparable time frame to children as assessed by the proportion of patients completing induction/consolidation and commencing the next phase of therapy - protocol M or high risk (HR) treatment - by day 94. Minimal residual disease (MRD) response stratified patients to HR treatment and transplantation. From 2012 to 2018, 86 patients were enrolled; 82 were eligible. Median age was 22 (range, 16-38) years. Induction/consolidation was equally deliverable in ALL06 as in Study 8. In ALL06, 41.5% (95%CI, 30.7-52.9) commenced protocol M or HR therapy by day 94 vs 39.3% in Study 8 (p=0.77). Median time to protocol M/HR treatment was 96 (IQR, 87.5-103) days in ALL06 vs 98 days in Study 8 (p=0.80). Induction mortality was 3.6%. With median follow up of 44 (1-96) months, estimated 3-year disease free survival (DFS) was 72.8% (95%CI, 62.8-82.7) and estimated 3-year overall survival (OS) was 74.9% (95%CI, 65.3-84.5%). End induction/consolidation MRD negativity rate was 58.6%. Body mass index (BMI) ≥30 and day 79 MRD positivity were associated with poorer DFS and OS. Pediatric therapy was safe and as deliverable in AYA patients as children with ALL. Intolerance of pediatric ALL induction/consolidation is not a major contributor to inferior outcomes in AYA ALL.
Pharmacology, Toxicology and Pharmaceutical Science
1
4%
Social Sciences
1
4%
Other
0
0%
Unknown
15
58%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 November 2021.
All research outputs
#3,023,999
of 23,310,485 outputs
Outputs from Blood Advances
#647
of 2,750 outputs
Outputs of similar age
#74,228
of 506,440 outputs
Outputs of similar age from Blood Advances
#34
of 174 outputs
Altmetric has tracked 23,310,485 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,750 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 506,440 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 174 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.
